share_log

Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $6

Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $6

Canaccord Genuity 维持对 Cardiol Therapeutics 的买入,将目标价上调
Benzinga ·  2023/05/19 07:55

Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $5 to $6.

Canaccord Genuity分析师爱德华·纳什维持Cardiol Therapeutics(纳斯达克股票代码:CRDL)的买入,并将目标股价从5美元上调至6美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发